# Steven De Vleeschouwer

## List of Publications by Year in descending order



| | | | |
|---|---|---|---|
| 72 papers | 3,615 citations | 172207 29 h-index | 143772 57 g-index |
| 80 all docs | 80 docs citations | 80 times ranked | 4651 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Gliomas: Diffusion Kurtosis MR Imaging in Grading. Radiology, 2012, 263, 492-501. | 3.6 | 311 |
| 2 | Single-cell profiling of myeloid cells in glioblastoma across species and disease stage reveals macrophage competition and specialization. Nature Neuroscience, 2021, 24, 595-610. | 7.1 | 288 |
| 3 | Postoperative Adjuvant Dendritic Cellâ€“Based Immunotherapy in Patients with Relapsed Glioblastoma Multiforme. Clinical Cancer Research, 2008, 14, 3098-3104. | 3.2 | 237 |
| 4 | Newcastle disease virotherapy induces longâ€term survival and tumorâ€specific immune memory in orthotopic glioma through the induction of immunogenic cell death. International Journal of Cancer, 2015, 136, E313-25. | 2.3 | 165 |
| 5 | Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study. British Journal of Cancer, 2004, 91, 1656-1662. | 2.9 | 161 |
| 6 | Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial. Cancer Immunology, Immunotherapy, 2012, 61, 2033-2044. | 2.0 | 136 |
| 7 | Formulations for Intranasal Delivery of Pharmacological Agents to Combat Brain Disease: A New Opportunity to Tackle GBM?. Cancers, 2013, 5, 1020-1048. | 1.7 | 126 |
| 8 | Trial watch: dendritic cell vaccination for cancer immunotherapy. OncoImmunology, 2019, 8, 1638212. | 2.1 | 125 |
| 9 | Development of siRNA-loaded chitosan nanoparticles targeting Galectin-1 for the treatment of glioblastoma multiforme via intranasal administration. Journal of Controlled Release, 2016, 227, 71-81. | 4.8 | 123 |
| 10 | Adjuvant dendritic cellâ€based tumour vaccination for children with malignant brain tumours. Pediatric Blood and Cancer, 2010, 54, 519-525. | 0.8 | 120 |
| 11 | Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study. Journal of Neuro-Oncology, 2010, 99, 261-272. | 1.4 | 119 |
| 12 | Sensitization of glioblastoma tumor micro-environment to chemo- and immunotherapy by Galectin-1 intranasal knock-down strategy. Scientific Reports, 2017, 7, 1217. | 1.6 | 105 |
| 13 | DC vaccination with anti-CD25 treatment leads to long-term immunity against experimental glioma. Neuro-Oncology, 2009, 11, 529-542. | 0.6 | 94 |
| 14 | Dendritic Cell Therapy of Highâ€Grade Gliomas. Brain Pathology, 2009, 19, 694-712. | 2.1 | 90 |
| 15 | MR perfusion and diffusion imaging in the follow-up of recurrent glioblastoma treated with dendritic cell immunotherapy: a pilot study. Neuroradiology, 2011, 53, 721-731. | 1.1 | 72 |
| 16 | Gliomaâ€derived galectinâ€1 regulates innate and adaptive antitumor immunity. International Journal of Cancer, 2014, 134, 873-884. | 2.3 | 71 |
| 17 | Galectin-1 in Melanoma Biology and Related Neo-Angiogenesis Processes. Journal of Investigative Dermatology, 2012, 132, 2245-2254. | 0.3 | 64 |
| 18 | Preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma. OncoImmunology, 2017, 6, e1295903. | 2.1 | 64 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | DENDRITIC CELL VACCINATION IN PATIENTS WITH MALIGNANT GLIOMAS. Neurosurgery, 2006, 59, 988-1000. | 0.6 | 61 |
| 20 | Transient local response and persistent tumor control in a child with recurrent malignant glioma: treatment with combination therapy including dendritic cell therapy. Journal of Neurosurgery: Pediatrics, 2004, 100, 492-497. | 0.8 | 56 |
| 21 | Primary brain tumours, meningiomas and brain metastases in pregnancy: Report on 27 cases and review of literature. European Journal of Cancer, 2014, 50, 1462-1471. | 1.3 | 54 |
| 22 | Dynamic stroma reorganization drives blood vessel dysmorphia during glioma growth. EMBO Molecular Medicine, 2017, 9, 1629-1645. | 3.3 | 54 |
| 23 | Trial watch: Dendritic cell (DC)-based immunotherapy for cancer. OncoImmunology, 2022, 11, . | 2.1 | 54 |
| 24 | Living with a high-grade glioma: A qualitative study of patients' experiences and care needs. European Journal of Oncology Nursing, 2015, 19, 383-390. | 0.9 | 51 |
| 25 | What the neurosurgeon should know about hemangioblastoma, both sporadic and in Von Hippel-Lindau disease: A literature review. , 2013, 4, 145. | | 51 |
| 26 | Irradiation of necrotic cancer cells, employed for pulsing dendritic cells (DCs), potentiates DC vaccine-induced antitumor immunity against high-grade glioma. OncoImmunology, 2016, 5, e1083669. | 2.1 | 49 |
| 27 | Defining pseudoprogression in glioblastoma multiforme. European Journal of Neurology, 2013, 20, 1335-1341. | 1.7 | 48 |
| 28 | SLIT2/ROBO signaling in tumor-associated microglia and macrophages drives glioblastoma immunosuppression and vascular dysmorphia. Journal of Clinical Investigation, 2021, 131, . | 3.9 | 46 |
| 29 | Uptake and presentation of malignant glioma tumor cell lysates by monocyte-derived dendritic cells. Cancer Immunology, Immunotherapy, 2005, 54, 372-382. | 2.0 | 42 |
| 30 | Altered galectin-1 serum levels in patients diagnosed with high-grade glioma. Journal of Neuro-Oncology, 2013, 115, 9-17. | 1.4 | 42 |
| 31 | Risk Analysis of Thrombo-Embolic and Recurrent Bleeding Events in the Management Of Intracranial Haemorrhage Due to Oral Anticoagulation. Acta Chirurgica Belgica, 2005, 105, 268-274. | 0.2 | 39 |
| 32 | DNA methylation based glioblastoma subclassification is related to tumoral T-cell infiltration and patient survival. Neuro-Oncology, 2021, 23, 240-250. | 0.6 | 31 |
| 33 | Glioblastoma: To Target the Tumor Cell or the Microenvironment?. , 0, , 315-340. | | 31 |
| 34 | Effect of awake craniotomy in glioblastoma in eloquent areas (GLIOMAP): a propensity score-matched analysis of an international, multicentre, cohort study. Lancet Oncology, The, 2022, 23, 802-817. | 5.1 | 31 |
| 35 | Persistent IL-10 production is required for glioma growth suppressive activity by Th1-directed effector cells after stimulation with tumor lysate-loaded dendritic cells. Journal of Neuro-Oncology, 2007, 84, 131-140. | 1.4 | 28 |
| 36 | Development and validation of a fully GMP-compliant production process of autologous, tumor-lysate-pulsed dendritic cells. Cytotherapy, 2014, 16, 946-964. | 0.3 | 27 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Family Caregivers of Patients With a High-Grade Glioma. Cancer Nursing, 2015, 38, 406-413. | 0.7 | 26 |
| 38 | Immunotherapy for malignant gliomas: emphasis on strategies of active specific immunotherapy using autologous dendritic cells. Child's Nervous System, 2005, 21, 7-18. | 0.6 | 25 |
| 39 | Immune Suppression during Oncolytic Virotherapy for High-Grade Glioma; Yes or No?. Journal of Cancer, 2015, 6, 203-217. | 1.2 | 24 |
| 40 | Immunogenic cell death and its therapeutic or prognostic potential in high-grade glioma. Genes and Immunity, 2022, 23, 1-11. | 2.2 | 24 |
| 41 | Galectin-1 and immunotherapy for brain cancer. Expert Review of Neurotherapeutics, 2011, 11, 533-543. | 1.4 | 23 |
| 42 | Stratification according to HGG-IMMUNO RPA model predicts outcome in a large group of patients with relapsed malignant glioma treated by adjuvant postoperative dendritic cell vaccination. Cancer Immunology, Immunotherapy, 2012, 61, 2105-2112. | 2.0 | 23 |
| 43 | Characterization of PDâ€1 upregulation on tumorâ€infiltrating lymphocytes in human and murine gliomas and preclinical therapeutic blockade. International Journal of Cancer, 2017, 141, 1891-1900. | 2.3 | 23 |
| 44 | Technical advancement in regulatory T cell isolation and characterization using CD127 expression in patients with malignant glioma treated with autologous dendritic cell vaccination. Journal of Immunological Methods, 2010, 352, 169-173. | 0.6 | 22 |
| 45 | Optimized preoperative motor cortex mapping in brain tumors using advanced processing of transcranial magnetic stimulation data. NeuroImage: Clinical, 2019, 21, 101657. | 1.4 | 16 |
| 46 | Safe surgery for glioblastoma: Recent advances and modern challenges. Neuro-Oncology Practice, 2022, 9, 364-379. | 1.0 | 14 |
| 47 | The incidence of postoperative cerebrospinal fluid leakage after elective cranial surgery: a systematic review. Neurosurgical Review, 2022, 45, 1827-1845. | 1.2 | 13 |
| 48 | Ependymomas of the filum terminale: The role of surgery and radiotherapy. , 2012, 3, 76. | | 12 |
| 49 | Re-irradiation or re-operation followed by dendritic cell vaccination? Comparison of two different salvage strategies for relapsed high-grade gliomas by means of a new prognostic model. Journal of Neuro-Oncology, 2015, 124, 325-332. | 1.4 | 10 |
| 50 | Long-lasting, Complete Exclusion of a Large Galenic Dural Arteriovenous Fistula After Clipping of the Central Venous Aneurysm of the Vein of Galen: Case Report. Neurosurgery, 2011, 68, E571-E574. | 0.6 | 9 |
| 51 | Results of endoscopic third ventriculostomy in elderly patients â‰¥65 years of age. Clinical Neurology and Neurosurgery, 2015, 130, 48-54. | 0.6 | 8 |
| 52 | 5-Aminolevulinic acid for recurrent malignant gliomas: A systematic review. Clinical Neurology and Neurosurgery, 2020, 195, 105913. | 0.6 | 8 |
| 53 | Resection and Immunotherapy for Recurrent Grade III Glioma. ISRN Immunology, 2012, 2012, 1-9. | 0.7 | 8 |
| 54 | Should dendritic cell-based tumor vaccination be incorporated into standard therapy for newly diagnosed glioblastoma patients?. Expert Review of Neurotherapeutics, 2012, 12, 1173-1176. | 1.4 | 7 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Screening for Intracranial Aneurysms in Individuals with a Positive First-Degree Family History: A Systematic Review. World Neurosurgery, 2021, 151, 235-248.e5. | 0.7 | 7 |
| 56 | Towards real-time intraoperative tissue interrogation for REIMS-guided glioma surgery. Journal of Mass Spectrometry and Advances in the Clinical Lab, 2022, 24, 80-89. | 1.3 | 7 |
| 57 | Global comparison of awake and asleep mapping procedures in glioma surgery: An international multicenter survey. Neuro-Oncology Practice, 2022, 9, 123-132. | 1.0 | 6 |
| 58 | Dendritic cell vaccination for glioblastoma multiforme: review with focus on predictive factors for treatment response. ImmunoTargets and Therapy, 2014, 3, 55. | 2.7 | 5 |
| 59 | Recurring Glioblastoma: A Case for Reoperation?. , 0, , 281-296. | | 5 |
| 60 | Letter: Maximizing the extent of resection and survival benefit of patients in glioblastoma surgery: High-field iMRI versus conventional and 5-ALA-assisted surgery. European Journal of Surgical Oncology, 2014, 40, 1384-1385. | 0.5 | 3 |
| 61 | Automated speech analysis to improve TMS-based language mapping: Algorithm and proof of concept. Brain Stimulation, 2020, 13, 267-269. | 0.7 | 3 |
| 62 | Maximizing extent of resection while minimizing the risk of neurological morbidity in glioma patients: a novel grading scale to translate these surgical goals into a merged onco-functional clinical outcome. Neuro-Oncology, 2021, 23, 504-505. | 0.6 | 3 |
| 63 | Irradiation of necrotic tumor cells used to pulse dendritic cells (DCs) potentiates DC vaccine-induced anti-tumor immunity in a mouse model of high-grade glioma. , 2014, 2, . | | 1 |
| 64 | A posttraumatic pontomedullary rent with good outcome. Acta Neurochirurgica, 2016, 158, 577-579. | 0.9 | 1 |
| 65 | Intracerebral abscess due to Cutibacterium acnes after lung transplantation. Transplant Infectious Disease, 2021, 23, e13398. | 0.7 | 1 |
| 66 | Stroke rate after external fractionated radiotherapy for benign meningioma. Journal of Neuro-Oncology, 2021, 152, 99-106. | 1.4 | 1 |
| 67 | Treatment of ruptured subclavian steal flow-related vertebrobasilar junction aneurysms: Case report on surgical and endovascular considerations from two cases. International Journal of Surgery Case Reports, 2022, 90, 106744. | 0.2 | 1 |
| 68 | Adjuvant dendritic cell-based tumor vaccination for children with malignant brain tumors: preliminary results. World Neurosurgery, 2009, 71, 135. | 1.3 | 0 |
| 69 | 36 Clinical applications â€“ lessons from pediatrics. European Journal of Cancer, Supplement, 2009, 7, 12. | 2.2 | 0 |
| 70 | High-Grade Gliomas: Dendritic Cell Therapy. , 2011, , 313-333. | | 0 |
| 71 | Dendritic cell vaccination for glioblastoma multiforme: Clinical experience and future directions. , 2014, , . | | 0 |
| 72 | MGMT promoter methylation and IDH1 mutation as prognostic markers for a favorable clinical outcome in patients with glioblastoma multiforme.. Journal of Clinical Oncology, 2010, 28, 2053-2053. | 0.8 | 0 |